143 F. Supp. 3d 188
D.N.J.2015Background
- Otsuka owns NDA for Ability (aripiprazole tablets) and listed four patents in the Orange Book covering multiple tablet strengths.
- Apotex filed an ANDA with a Paragraph IV certification seeking approval to market generic aripiprazole tablets and provided Otsuka detailed ANDA materials and samples before suit.
- Otsuka sued for patent infringement; Apotex counterclaimed for unlawful monopolization (sham litigation under the Sherman Act) and for patent misuse (declaratory judgment of unenforceability).
- Apotex alleges Otsuka filed objectively baseless suits despite detailed noninfringement evidence and did so to maintain a monopoly and delay generic entry.
- Otsuka moved to dismiss both counterclaims under Rule 12(b)(6) or alternatively to bifurcate and stay them pending resolution of the patent issues.
- The court denied dismissal of the antitrust and patent-misuse counterclaims (finding the allegations plausible) but granted bifurcation and a stay of those counterclaims pending resolution of the infringement litigation.
Issues
| Issue | Plaintiff's Argument (Otsuka) | Defendant's Argument (Apotex) | Held |
|---|---|---|---|
| Antitrust standing / antitrust injury | Apotex lacks antitrust standing because it is not an approved competitor and fails to plead antitrust injury | Apotex is an ANDA filer intending to sell in U.S.; its allegations show litigation was used to block market entry and maintain monopoly | Denied dismissal — Apotex has standing as an ANDA filer and pleaded plausible antitrust injury |
| Noerr-Pennington immunity / sham litigation exception | Otsuka’s litigation is presumptively immune; Apotex’s allegations are conclusory and fail to show objectively baseless suits | Apotex alleges Otsuka sued immediately after receiving extensive noninfringement proof (13,000+ pages), supporting sham-litigation inference | Denied dismissal — allegations plausibly overcome immunity at pleading stage; factual issues for discovery |
| Patent misuse claim sufficiency | Patent misuse claim fails as a matter of law; Apotex didn’t allege expansion of patent scope | Apotex alleges Otsuka used patents to impermissibly broaden temporal/physical scope to prolong monopoly and delay entry | Denied dismissal — pleaded facts sufficiently allege misuse (impermissible broadening) |
| Bifurcation and stay of antitrust/misuse counterclaims | Otsuka argued for severance and stay to avoid complex, premature antitrust discovery | Apotex consented to bifurcation but sought concurrent antitrust fact discovery | Granted — court bifurcated and stayed the antitrust and misuse counterclaims pending resolution of the patent infringement claims |
Key Cases Cited
- Ashcroft v. Iqbal, 556 U.S. 662 (pleading standard: plausibility required)
- Bell Atl. Corp. v. Twombly, 550 U.S. 544 (pleading standard and antitrust complaint requirements)
- Ethypharm S.A. France v. Abbott Labs., 707 F.3d 223 (antitrust standing analysis for ANDA/market barriers)
- Eastern R.R. Presidents Conference v. Noerr Motor Freight, 365 U.S. 127 (Noerr-Pennington doctrine — petitioning immunity)
- Prof'l Real Estate Investors v. Columbia Pictures Indus., 508 U.S. 49 (sham litigation exception elements)
- Princo Corp. v. Int'l Trade Comm'n, 616 F.3d 1318 (patent misuse inquiry: improper broadening of physical/temporal scope)